

Vivimed

For Immediate Release

September 21, 2017

Vivimed's FDF facility in Jeedimetla Obtained Ukraine GMP Approval

The GMP approval also includes 3 new product registrations


Hyderabad, India, September 21, 2017 – Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that its FDF manufacturing facility located in Jeedimetla, near Hyderabad inspected in August 2017 by the Ukraine ministry of Health, has been approved and accredited with GMP Certification effective September 2017. Ukraine is a member Country of PICS, whose members include many European Countries.

The GMP approval also includes 3 new product registrations.

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For VIVIMED LABS LTD.


Company Secretary